Polyphron
Summary Updated Sep 18, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Polyphron is a New York–based biotech developing artificial human biology by combining physical tissue manufacturing with AI simulation, producing donor-diverse human tissues that serve as a verification substrate for testing biological interventions at scale 12. The company’s stated aim is to close the gap between AI-generated interventions and the slower biology required to validate them 1. Its founding team comes out of Google DeepMind, the Broad Institute and Harvard Medical School, Ginkgo Bioworks, and prior AI startup exits 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-09-17 | Seed | $20M | Quiet Capital | Gradient, Haystack, Compound 234 |
What Investors Say
No independently sourced investor quotes beyond announcement boilerplate at time of profile creation.
What Founders Say
No independently sourced founder testimonials found at time of profile creation.
Sources
-
Polyphron company website, “Home,” accessed September 18, 2026. https://polyphron.com/↩↩↩
-
AlleyWatch, “The AlleyWatch Startup Daily Funding Report: 9/17/2026,” September 17, 2026. https://alleywatch.com/2026/09/the-alleywatch-startup-daily-funding-report-9-17-2026/↩↩
-
Axios Pro Rata (Dan Primack), deal listing for Polyphron $20M seed, September 17, 2026. https://www.axios.com/newsletters/axios-pro-rata↩
-
Quiet Capital portfolio page, accessed September 18, 2026. https://quiet.com/portfolio/ — Polyphron is listed among Quiet Capital’s active portfolio companies, confirming the lead investor relationship. ↩